AQR Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

AQR Capital Management LLC purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 202,241 shares of the biotechnology company’s stock, valued at approximately $1,155,000. AQR Capital Management LLC owned about 0.14% of Aurinia Pharmaceuticals at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Banque Cantonale Vaudoise lifted its stake in Aurinia Pharmaceuticals by 126.6% in the 2nd quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 5,410 shares in the last quarter. Virtu Financial LLC purchased a new position in Aurinia Pharmaceuticals during the first quarter worth approximately $78,000. Sierra Summit Advisors LLC acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $202,000. China Universal Asset Management Co. Ltd. grew its holdings in Aurinia Pharmaceuticals by 67.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 27,802 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 11,189 shares in the last quarter. Finally, PFG Investments LLC grew its holdings in Aurinia Pharmaceuticals by 37.9% in the 2nd quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 7,900 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

NASDAQ AUPH opened at $7.08 on Friday. The stock has a fifty day simple moving average of $6.61 and a 200-day simple moving average of $5.78. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18. The stock has a market cap of $1.01 billion, a PE ratio of -20.82 and a beta of 1.44. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.05.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $57.10 million during the quarter, compared to analyst estimates of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. Aurinia Pharmaceuticals’s revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.08) earnings per share. Equities analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

AUPH has been the topic of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, insider Scott Michael Habig sold 18,249 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the transaction, the insider now directly owns 456,338 shares in the company, valued at $2,423,154.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.30% of the stock is owned by corporate insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.